NEXGEL, Inc. (NASDAQ: NXGL) announced the completion of its acquisition of Celularity’s degenerative wound segment during a recent shareholder update conference call. This move marks a pivotal advancement for the company, transforming it into a more scalable and diversified medical technology enterprise.
Key Announcement from CEO
Adam Levy, Chief Executive Officer, President, and Director of NEXGEL, detailed the transaction’s closure, which was revealed earlier that day. The deal triples the company’s revenue run rate, positioning NEXGEL for accelerated growth in the medical technology sector.
Conference Call Overview
The call featured introductions by Valter Pinto, Managing Director at KCSA Strategic Communications. Pinto reminded participants that forward-looking statements are subject to risks and uncertainties outlined in the company’s SEC filings. Actual results may vary materially due to various factors.
Levy expressed gratitude to attendees and emphasized the strategic importance of the acquisition. This step evolves NEXGEL’s business model toward greater diversification and scalability.
Forward-Looking Statements Caution
Officials noted that the company holds no obligation to update forward-looking statements unless required by law, underscoring potential variances from projections based on ongoing business risks.
